Former Pacific Edge chief executive joins medicinal cannabis company.
David Darling has been appointed as an independent director on the board at Helius Therapeutics.
Darling was replaced as chief executive of Pacific Edge in January after 19 years in the role. The NZX and ASX-listed business is focused on commercialising its bladder cancer diagnostics tests in global markets.
Helius Therapeutics claims to be New Zealand’s largest medicinal cannabis company and focuses on research, innovation, manufacturing, and commercialisation. The 100% Kiwi-owned private company has an 8,800sqm medicines manufacturing and indoor cannabis cultivation complex in East Auckland.
“Helius is at the forefront of tomorrow’s plant-based medicines. It’s an incredibly exciting and fast-growing industry, with Helius already delivering,” Darling said.
He said he was excited to join the board and had been impressed by the investors, board members, management, and staff.
“Helius is a trailblazer and leader in New Zealand’s newest industry,” he said.
“Darling’s arrival represents an exciting phase in our business as we begin to execute our international growth phase,” Helius chief executive Carmen Doran said.
Darling replaces Helius founder, JP Schmidt, who is stepping down after five years.
This is supplied content and not commissioned or paid for by NBR.
